


2021 PROGRAM NEWSLETTER



— 1 S T A N N U A L —

NEUROFIBROMATOSIS YOUNG INVESTIGATORS' FORUM

An Academic Research Forum Focused on Research
Productivity, Career Development, and Community-Building
for Junior Faculty, Fellows, and Postdoctoral Researchers
Conducting Impactful Work in Neurofibromatosis

SEPTEMBER 23-25, 2021

Conducted virtually from The Houstonian Hotel in Houston, Texas

www.ceconcepts.com/NFYIF | Follow us on Twitter @NFYIForum

Presented by
Creative Educational Concepts, LLC
in collaboration with the
Children's Tumor Foundation.



This activity is supported through
an independent educational
grant from AstraZeneca.

Dear Colleagues,

We are all fortunate to be working during a time of such rapid advancement in the field of neurofibromatosis (NF). Despite the challenging and complex nature of NF, the advent of targeted medical therapies, as well as novel diagnostic techniques and a number of other nascent treatment approaches, have recently galvanized much-needed paradigmatic change in a disease historically characterized by limited treatment options, patient morbidity, and bleak prognoses. It is, indeed, an exciting time for patients and clinicians alike. But in order to sustain and expand this positive momentum, the next generation of NF researchers must be cultivated, mentored, and empowered to build upon existing successes and catalyze NF therapeutics into a new era. The inaugural Neurofibromatosis Young Investigators' Forum (NFYIF) sought to do exactly that, convening high-potential, early-career NF investigators from all across the country and provisioning a forum in which they could share their work with peers and premier NF thought leaders, who provided expert training and constructive feedback to help improve both scientific quality and presentation value. A truly world-class panel of Expert Judge Mentors selected a total of 18 young investigators (clinician scientists, research scientists, clinical fellows, and PhD postdoctoral fellows) based on blinded reviews of submitted abstracts. The invited young investigators presented their work and received feedback from not only the expert panel, but from peers/future collaborators and professional medical communication coaches.




The inaugural NFYIF was widely considered a robust success. Young investigator research quality and complexity were illustrative of the very bright future of NF, and poignant sessions led by patients and caregivers personified the empiric “why” behind all that we do. Young investigators rated the meeting highly during post-meeting evaluation, with some calling the NFYIF “the best virtual meeting they have ever attended.”

On behalf of the Expert Faculty Mentors, we sincerely congratulate the 2021 NFYIF class of young investigators on their fantastic work! We look forward to your future successes and hope the connections and friendships you made at the NFYIF will last a lifetime.

Sincerely,


Bruce R. Korf, MD, PhD (Chair)

Andrea M. Gross, MD (Co-chair)




The Neurofibromatosis Young Investigators' Forum (NFYIF) is a unique educational opportunity designed specifically for U.S.-based young investigators (MD, DO, and/or PhD) who are pursuing a career in academic research focused on neurofibromatosis across basic, translational, and clinical research settings. As a competitive academic research program, the NFYIF provides a professional venue at which oncology junior faculty and fellows from across the country are invited to submit an abstract of their unpublished, original research to a panel of expert faculty for assessment.

The 2021 NFYIF—our inaugural initiative—was designed to ensure a high level of science, quality, and participation as a means of laying a substantive and healthy foundation for future years to build upon. CEC Oncology composed and conducted a robust Call for Abstracts (CFA) among clinician scientists, research scientists, clinical fellows, and postdoctoral fellows involved in neurofibromatosis research across the full spectrum of disease (NF1, NF2, and schwannomatosis). After a rigorous, blinded selection process as determined by top scientific experts and thought leaders in the field, a highly select group of 18 researchers were invited to present their data to peers and an esteemed panel of Expert Faculty Judge Mentors in a modified NIH scoring format. In an effort to augment the professional development aspects of this forum, a professional coach with a long history working with scientists to improve their ability to clearly present complex data, effectively and articulately address challenging questions, and manage tight time windows with professionalism and finesse was brought in and made available to all young investigators. The overarching goal of this initiative was and is to help identify, cultivate, and prepare young investigators for successful careers that help advance the field of neurofibromatosis via a “connect the unconnected” approach focused on collaboration, collegiality, and community-building, which are all especially crucial in the research niche of a rare disease like NF. Our inaugural NFYIF installment robustly achieved this goal, and in so doing, effectively laid the groundwork for future successes.



Kyle Williams, PhD @kylenago · 9/24/21 ...
 Always happy to share our work to #EndNF. Thanks to @ChildrensTumor and @NFYIFForum for the opportunity to participate and hear so many outstanding talks over the last two days.

“ I THINK THIS WAS VERY BENEFICIAL WITH REGARD TO NETWORKING, ENGAGING WITH OTHER RESEARCHERS AT A SIMILAR TRAINING LEVEL, AND ADVANCING THE SCIENCE OF EVALUATING NF1. I ALSO FOUND THE PATIENT REPRESENTATIVES INSPIRING AND WAS SO IMPRESSED AND MOVED BY THEIR STORIES.



Dr. Stephanie Joy Bouley @... · 9/24/21 ...
 Grateful to have had this opportunity! 🇺🇸
 NFYIF @NFYIFForum · 9/24/21
 Dr. @SJB1120 from @MGHNeurology presented her results on CRISPR-based gene therapies for #NF1. 🧬🧠
 @MassGeneralNews @MassGenBrigham @ChildrensTumor #NFYIF21 #EndNF #RareDisease

Himanshi Bhatia @Himanshi... · 9/24/21 ...
 Had a wonderful time presenting my work to the NF community. Looking forward to other exciting talks!
 @AngelaHirbe

\$10,000 Grant

The Neurofibromatosis Distinguished Young Investigator Award provides recognition for junior faculty who continue their dedication and sustained research efforts in neurofibromatosis. This year's Neurofibromatosis Distinguished Young Investigators' Award was presented to:

2021 JUNIOR FACULTY

CLINICIAN SCIENTIST AND RESEARCH SCIENTIST

Melissa Perrino, MD

Cincinnati Children's Hospital Medical Center

Complementing MEK Inhibition in NF1: C5aR-antagonism in Combination with MEK Inhibition Reduces Plexiform Neurofibroma Growth, Demonstrating the Importance and Targetability of the Tumor Micro-environment

Melissa Perrino is a pediatric hematology/oncology instructor at St Jude Children's Research Hospital. She completed medical school training at Wright State University in Dayton, Ohio, pediatrics residency training at the University of Tennessee Health Sciences in Memphis, Tennessee, and returned to Ohio for pediatric hematology/oncology fellowship at Cincinnati Children's Hospital Medical Center (CCHMC).

During her oncology training at CCHMC, Dr. Perrino entered the lab of Nancy Ratner studying neurofibromatosis type I. Her focus in the lab was to identify combination therapy for plexiform neurofibroma treatment by targeting the immune microenvironment in combination with MEK inhibition. She will now transition to the clinic with NF1 patients and others with cancer predisposition syndromes in hopes of bringing more therapy to these patients with precision-targeted approaches.

Dr. Perrino is currently a clinical attending within the Department of Oncology and Hereditary Cancer Predisposition, with a focus in cancer predisposition syndromes, molecular oncology, and applying targeted therapeutics to patient care in solid tumor and neuro oncology.

"The NF Young Investigators' Forum has been a fantastic way to talk with others in the field of NF1 from basic sciences to clinical research. Participating in this forum has helped me show my research to others in the field and get valuable feedback. It was a great way to hear about other projects and also be motivated to continue my own!"

"This award will be instrumental as I start my career in cancer predisposition and genetic influences of tumorigenesis. I have recently finished training and will be starting new clinical projects; I am hoping to build from my bench research in NF1 into the clinical realm. The money from this award will help with resources to get these projects started."





CLINICIAN SCIENTIST AND RESEARCH SCIENTIST

1ST RUNNER UP

Ina Ly, MD

Massachusetts General Hospital

A Multi-center Radiomics-based Model to Differentiate between Neurofibromatosis Type 1-associated Plexiform Neurofibromas and Malignant Peripheral Nerve Sheath Tumors

"The interaction with faculty from other institutions and disciplines has provided me with valuable insights into strategies for networking, grant applications, and professional development at the national and international level."

"[The award will be used for] educational and career development, including courses and travel to conferences."



2ND RUNNER UP

Daochun Sun, PhD

Medical College of Wisconsin

MPNST Cancer Stem Cells Promote the Metastatic Progression

"First, I realize that I am not alone in building my career, and many young scientists are developing great ideas for their future. Second, the mentors do help. This is an excellent chance to let them know me or get familiar with me. Third, it let me know that I need to get prepared because of many challenges ahead."

"The award will be used toward my career network building with internal researchers and clinicians."



CLINICAL FELLOWS

FIRST PLACE

Russell Taylor Sundby, MD

National Cancer Institute

Cell-free DNA Ultra-low-pass Whole Genome Sequencing to Distinguish Malignant Peripheral Nerve Sheath Tumor (MPNST) from Its Benign Precursor Lesion

"NFYIF was a fantastic opportunity to network with other young investigators and to lay the foundation for future collaborations. Already I have several new threads of communication with participants discussing exciting, new, collaborative projects. Additionally, I was able to meet and learn from patient advocates as well as established physician-scientists in the field. This was a fantastic opportunity that I hope to continue to be able to participate in!"

"I am excited to apply the NFYIF grant award toward the sequencing of plasma from patients with NF1. Applying this technology to new populations (such as patients with atypical neurofibromas) and using advanced sequencing and analytic techniques holds the promise to build on our previous work for better earlier detection of malignancy and classification of lesions using circulating biomarkers."

SECOND PLACE

Stephanie Brosius, MD, PhD

Children's Hospital of Philadelphia

Characteristics of Moyamoya Syndrome in Pediatric Patients with Neurofibromatosis Type 1

"The networking from the NFYIF was fantastic, and the feedback on my project and the career advice were outstanding. I now have several new ideas on how to move forward and expand my research to reach the next phase in my career."

"This award will help to fund a technician who will assist me in the performance of experiments to translate work from clinic to the bench. Having an additional set of hands will provide me with the opportunity to continue to make progress on my research while I finish my clinical training."



PHD/POSTDOCTORAL FELLOWS

FIRST PLACE

Xiyuan Zhang, PhD

National Cancer Institute

Single-cell Omics Reveals Diverse Epigenetic and Transcriptomic Reprogramming of NF1-deficient Cells through the Loss of PRC2 in MPNST



“Being selected to participate in the NFYIF has been a tremendous educational and networking opportunity for me. I really appreciate the opportunity to be able to 1) know other wonderful young investigators who share the same goal of “END NF” with me—it was great to get to know the exciting science they are working on; 2) participate in small group discussions on topics we are interested with our wonderful faculties—this is a rare opportunity for us to learn from successful NF researchers, especially during a pandemic; and 3) get motivated by our patient representatives who shared their unique perspectives as a patient—it is always motivating to learn that our work may be meaningful for someone who is affected by this disease. I am very grateful for this opportunity.”

“I am going to use the grant award to further validate the functions of the identified oncogenic transcription factors in driving the malignant transformation and defining the malignant transcriptional program in NF1-associated nerve tumors. Ultimately, by better understanding the transcriptional control, we hope to design targeted therapies to treat the transcriptional addiction detected in MPNST.”

SECOND PLACE

Kevin Joseph Bruemmer, PhD

Stanford University

Chemoproteomic Approaches for Identifying the Roles of Glycosylation in Neurofibromatosis 1



“The NFYIF allowed me to connect with other NF researchers at the same career stage as me, which really enabled the formation of a supportive community. The faculty mentors offered great advice for how to navigate a career in NF research, and I feel more confident in my ability to become a leading member of the NF research community in years to come.”

“I plan to use this grant award to continue my research in identifying sites of glycosylation/phosphorylation crosstalk in NF1, and hopefully finish up a publication related to the work presented at the conference.”



Himanshi Bhatia, PhD
Postdoctoral Research Associate
Washington University–St. Louis
Evaluating Chromosome 8 Drivers for MPNST Progression



Stephanie Joy Bouley, PhD
Research Fellow
Massachusetts General Hospital
Developing CRISPR-based Gene Therapies for Neurofibromatosis Type 1



Stephanie Brosius, MD, PhD
Neuro-oncology Fellow
Children’s Hospital of Philadelphia
Characteristics of Moyamoya Syndrome in Pediatric Patients with Neurofibromatosis Type 1



Kevin Joseph Bruemmer, PhD
Postdoctoral Fellow
Stanford University
Chemoproteomic Approaches for Identifying the Roles of Glycosylation in Neurofibromatosis 1



Emma Celano, MD
Neurosurgery Resident
Rotating Clinical Research Fellow
MedStar Georgetown University Hospital
National Institutes of Health
Deep Phenotyping Reveals Germline Determinants of Disease Severity in Neurofibromatosis Type 2



Chelsea Kotch, MD, MSCE
Instructor
Children’s Hospital of Philadelphia
Predictors of Treatment-Refractory/Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1

13 INSTITUTIONS REPRESENTED



- CHILDREN’S HOSPITAL OF PHILADELPHIA
- CHILDREN’S NATIONAL HOSPITAL
- CINCINNATI CHILDREN’S HOSPITAL MEDICAL CENTER
- HARVARD MEDICAL SCHOOL
- MASSACHUSETTS GENERAL HOSPITAL
- MEDICAL COLLEGE OF WISCONSIN
- MEDSTAR GEORGETOWN UNIVERSITY HOSPITAL
- NATIONAL CANCER INSTITUTE (NCI/NIH)
- STANFORD UNIVERSITY
- THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
- UNIVERSITY OF CALIFORNIA–LOS ANGELES
- UNIVERSITY OF MINNESOTA
- WASHINGTON UNIVERSITY–ST LOUIS



Ina Ly, MD

Attending Neuro-Oncologist
Massachusetts General Hospital

A Multi-center Radiomics-based Model to Differentiate between Neurofibromatosis Type 1-associated Plexiform Neurofibromas and Malignant Peripheral Nerve Sheath Tumors



Vanessa Merker, PhD

Instructor in Investigation/Instructor in Neurology
Massachusetts General Hospital/Harvard Medical School

Clinical Trial Readiness for Schwannomatosis: Understanding the Natural History of Schwannomatosis-related Pain



Brian Na, MD

Pediatric Oncologist
University of California, Los Angeles

Cold Atmospheric Plasma (CAP) as a Treatment Modality for NF1-related Peripheral Nerve Sheath Tumors (PNSTs)



Melissa Perrino, MD

Instructor, Clinical Pediatrics, Oncology
Cincinnati Children's Hospital Medical Center

Complementing MEK Inhibition in NF1: C5aR-antagonism in Combination with MEK Inhibition Reduces Plexiform Neurofibroma Growth, Demonstrating the Importance and Targetability of the Tumor Micro-environment



Jay Pundavela, PhD

Research Associate
Cincinnati Children's Hospital Medical Center

T-cell Dependence of Neurofibroma Development and Growth





Namrata G.R. Raut, PhD

Research Fellow
Cincinnati Children's Hospital Medical Center

The Role of Schwann Cells in the Onset of Neuropathic Pain in Neurofibromatosis-1

PARTICIPANT DEMOGRAPHICS



PARTICIPANT CATEGORIES

- Junior Faculty Clinician Scientist
- Junior Faculty Research Scientist
- Clinical Fellow
- PhD/Postdoctoral Fellow



Carlos G. Romo, MD

Assistant Professor
The Johns Hopkins University School of Medicine

Clinical and Molecular Determinants of Outcome for Non-optic Pathway Gliomas in Adults with Neurofibromatosis Type 1



Daochun Sun, PhD

Assistant Professor
Medical College of Wisconsin

MPNST Cancer Stem Cells Promote the Metastatic Progression



Russell Taylor Sundby, MD

Advanced Clinical Fellow
National Cancer Institute- Pediatric Oncology Branch

Cell-free DNA Ultra-low-pass Whole Genome Sequencing to Distinguish Malignant Peripheral Nerve Sheath Tumor (MPNST) from Its Benign Precursor Lesion



Caitlin Tydings, MD

Research Associate
Children's National Hospital

Feasibility of Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment Targeting Distinct Nodular Lesions in Neurofibromatosis Type 1



Kyle B. Williams, PhD

Postdoctoral Fellow
University of Minnesota


Creation of NF1-associated Tumor Models Deficient for Polycomb Repressive Complex 2 and Identification of Therapeutic Vulnerabilities





Xiyuan Zhang, PhD

Research Fellow
National Cancer Institute

Single-cell Omics Reveals Diverse Epigenetic and Transcriptomic Reprogramming of NF1-deficient Cells through the Loss of PRC2 in MPNST



PARTICIPANT CREDENTIALS



DIVERSITY



Bruce R. Korf, MD, PhD
Chair
University of Alabama
Birmingham
Birmingham, AL



THIS WAS AN
OUTSTANDING GROUP
OF FACULTY
MENTORS.



Andrea M. Gross, MD
Co-chair
National Institutes of
Health
Washington, DC



D. Wade Clapp, MD
Indiana University
Bloomington, IN



I'VE LEARNED A LOT
FROM THE FACULTY AND
MY PEERS, IN TERMS OF
CAREER DEVELOPMENT
CHOICES, GRANT
APPLICATIONS, AND
PUBLISHING. I WILL
DEFINITELY BE USING
THESE IN MY CAREER.



AeRang Kim, MD, PhD
Children's National
Hospital
Washington, DC



Michael J. Fisher, MD
Children's Hospital of
Philadelphia
Philadelphia, PA



THE JUDGES WERE
FANTASTIC!



Nancy Ratner, PhD
Cincinnati Children's
Hospital Medical Center
Cincinnati, OH



Bill Riter
Mayfield Village, Ohio



Lilly Ann Brooks
Belle Isle, Florida

CTF MISSION MOMENT: PATIENT AND CAREGIVER PERSPECTIVES

The inaugural NFYIF brought together some of the world’s foremost NF thought leaders with a select group of high potential, high performing early-career NF researchers from across the United States; the result was the presentation of an immense amount of impactful NF science, formative professional and personal networking experiences, establishment of new peer-to-peer and peer-to-mentor relationships, and thus, an elemental shift in the trajectory of the NF field. And while those achievements are all crucially important, perhaps most important of all is actually the one thing undergirding everything else—the foundational “why” driving each and every person in attendance.

That “why” is, of course, the ultimate vision of improving care and optimizing outcomes for patients with neurofibromatosis. It is the empiric mission of the NFYIF and all those who attend, which is why young investigators called this year’s CTF Mission Moment “the highlight of the whole conference.”


The CTF Mission Moment gave the stage to two patients, one of whom is also a caregiver, and allowed them to share their personal NF journeys. Mr. Bill Riter and Ms. Lilly Ann Brooks inspired, informed, and actuated everyone in the (Zoom) room, effectively humanizing the science and leaving us all in awe of their strength, courage, and determination. The impact Bill and Lilly Ann had on the NFYIF was both tangible and intangible—immeasurable in the best possible way—and we very much hope to have them and many other patients/caregivers share their stories at future installments of the NFYIF.

MENTORING MOMENTS




I FELT SO SUPPORTED AND ENCOURAGED.

Guided by the overarching mission to cultivate, inform, and empower young neurofibromatosis researchers, the inaugural NFYIF provided an intimate setting in which our young investigators were privy to small-group Mentoring Moments sessions with our Expert Judge Mentors, all of whom are experienced and pre-eminent thought leaders in the field. Within these mentoring sessions, young investigators were offered actionable, real-world, tried-and-true advice on circumventing the prominent obstacles faced during early-career inflection points. During our opening Mentoring Moments session, Expert Judge Mentors Drs. Michael J. Fisher, Andrea M. Gross, and AeRang Kim discussed personal experiences illustrating the power of networking and community-building, and shared practical pearls for navigating the complex task of translating clinical concepts into funded protocols in the initiation and conductance of clinical trials. In our second Mentoring Moments session, Drs. Nancy Ratner, Bruce R. Korf, and D. Wade Clapp discussed the challenging—and critically important—skills of grant writing, publishing, and navigating the academic hierarchy. Perhaps most notably, throughout both sessions, our young investigators were granted unprecedented access to top NF Key Opinion Leaders and were provisioned one-on-one networking opportunities with peers, both of which possess the power to fundamentally alter their career trajectory and bolster future research productivity.




Bruce R. Korf, MD, PhD; Nancy Ratner, PhD; D. Wade Clapp, MD



Andrea M. Gross, MD; Michael J. Fisher, MD; AeRang Kim, MD PhD

PRESENTATION SKILLS ENHANCEMENT WORKSHOP

To augment the professional development aspects of the NFYIF, 2021 participants participated in individual coaching sessions with an expert from ListenWritePresent. Young investigators who attended the one-on-one pre-program coaching sessions received expert advice and critique of their presentation and public speaking skills, and were given a copy of the book *Listen. Write. Present.*, which was written by the ListenWritePresent team. In addition, the expert coach provided participants with tips for effectively answering questions about and defending their research.




2021 NFYIF Professional Scientific Communication Coach



Stephanie Roberson Barnard
Coach
Listen Write Present, LLC
Greensboro, NC

Change in Confidence in Ability to Defend Research



Mean Confidence on a scale of 1 to 4, where 1 is "not confident" and 4 is "extremely confident"

*p=0.0014

2021 NFYIF attendees ranked the Presentation Skills Workshop

3.5 out of 4.0.



I THINK THIS GAVE A GREAT OPPORTUNITY TO SHOWCASE UP-AND-COMING INVESTIGATORS AND TO ALLOW US TO FOSTER CONNECTIONS FROM THOSE ALREADY ESTABLISHED WITH MORE SENIOR RESEARCHERS.

HOW ATTENDING THE NFYIF WILL IMPACT YOUNG INVESTIGATORS' CAREERS



Brian Na (라상규, 羅相達) @b... · 9/24/21
So humbled to present our preliminary data and great feedback to further our science! So grateful for our @UCLAHealth NF team! @Leia_N_MD @Vchang_lab #NF1 #endNF #alwayslearning #NFYIF21



I LEARNED HOW TO CRITICALLY LISTEN TO AND PROVIDE FEEDBACK TO OTHER COLLEAGUES.



Taylor Sundby, MD @rtsundby · 9/24/21
It was an humbling to see my peer's amazing work showcased at #NFYIF21! I am looking forward to what I hope will be career long collaborations stemming from this forum! Highly recommended to all young #Neurofibromatosis researchers in future years! #EndNF @NFYIFForum



[I] GAINED USEFUL INSIGHTS INTO BASIC AND CLINICAL RESEARCH LANDSCAPE WHICH WILL HELP ME FORMULATE MY OWN RESEARCH QUESTIONS.



Bruce Korf @brkorf · 9/24/21
Replying to @NFYIForum and @CincyChildrens
Congratulations to Dr. Perrino and all the NF Young Investigators - amazingly impressive two days of presentations and major hope for the future of NF research!

RESEARCH PUBLICATIONS

Dicks A, **Bhatia H**, Clemens AW, et al. Improving scientific communication with service, education and career development. *Nat Biotechnol.* 2021;39(10):1309–1313.

Weber SM, Brossier NM, Prechtl A...**Brosius SN**, et al. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells. *Cell Commun Signal.* 2021;19(1):95.

Wolters PL, Reda S, Martin S...**Merker VL**, et al. Impact of the coronavirus pandemic on mental health and health care in adults with neurofibromatosis: Patient perspectives from an online survey. *Am J Med Genet A.* September 18, 2021. [Epub ahead of print.]

Bloeser K, McCarron KK, **Merker VL**, et al. "Because the country, it seems though, has turned their back on me": experiences of institutional betrayal among veterans living with Gulf War illness. *Soc Sci Med.* 2021;284:114211.

Ferdoushi A, Jamaluddin MFB, Li X, **Pundavela J**, et al. Secretome analysis of human schwann cells derived from malignant peripheral nerve sheath tumor. *Proteomics.* 2021:e2100063.

Szymanski JJ, **Sundby RT**, Jones PA, et al. Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study. *PLoS Med.* 2021;18(8):e1003734.

Tydings C, Yarmolenko P, Bornhorst M, et al. Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1. *Neurooncol Adv.* 2021;3(1):vdab116.



2ND ANNUAL NFYIF

SUMMER/FALL 2022
THE HOUSTONIAN HOTEL
HOUSTON, TEXAS

Abstract submission deadline
and details coming soon.

Please visit ceconcepts.com/NFYIF
for more information, and follow us
on Twitter [@NFYIForum](https://twitter.com/NFYIForum).

